Cell & Gene Therapy Unlocking Affordability: Cell Therapy Development Strategies to Expand Patient Access | ProBio CDMO 03-28-2024 / Dr. Li Chen, Sr. Director, Biologics Discovery Dept. ProBio VHH is a novel modality in antibody based therapy. Its naturally generated single-domain structure makes it an ideal building block in cell therapy. Learn More
Therapeutic Antibody Integrated antibody discovery solution for multi-pass transmembrane target | ProBio CDMO 11-28-2023 / Dr. Li Chen, Sr. Director, Biologics Discovery Dept. GPCR family is a one of those popular drug target in recent years. However, due to its natural of multi-pass transmembrane structure, it is considered as one of most the challenging type to develop therapeutic antibodies. Learn More
Therapeutic Antibody ADC One-stop Solution: Discovery, Development and Manufacturing | ProBio CDMO 09-21-2023 / Dr. Li Chen, Sr. Director of Biologics Discovery Dept., ProBio Antibody-drug conjugates, also known as ADC, is a combination of traditional chemotherapy and targeted biological molecule. Recent clinical development brings lots of attention to this particular therapy in oncology filed. In this webinar, we will briefly Learn More
Cell & Gene Therapy mRNA One-stop Solution: Plasmid, Linearized DNA, IVT-mRNA, mRNA-LNP and QC sharing | ProBio CDMO 09-05-2023 / Dr. Xiao Pan, Sr. Director, Platform R&D Dept. The production of mRNA therapeutics and vaccines is a complex process that begins with pDNA manufacturing and ends with fill and finish by using different delivery technologies. Learn More
Therapeutic Antibody Online Symposium: ProBox™ Platform for Complex Biologics CMC Development | ProBio CDMO 06-08-2023 / Rubin Jiang;Ying Li;Mengping Liu Online Symposium: ProBox™ Platform for Complex Biologics CMC Development Learn More
Cell & Gene Therapy Integrated one-stop solution for mRNA CMC | ProBio CDMO 03-28-2023 / Dr. Xiao Pan, Director of Platform R&D Dept., ProBio The production of mRNA therapeutics and vaccines is a complex process that begins with pDNA manufacturing and ends with fill and finish by using different delivery technologies. Currently, there are some mRNA candidates in late-stage trials or commercial Learn More
Therapeutic Antibody Integrated ADC discovery strategy and antibody/protein cell line development expertise sharing | ProBio CDMO 03-02-2023 / Dr. Li Chen, Director of Biologics Discovery Dept., ProBio Integrated ADC discovery strategy and antibody/protein cell line development expertise sharing Learn More
Therapeutic Antibody Don’t miss ProBio and GlyTherix Live Webinar on 6th December | ProBio CDMO 12-06-2022 / Brad Walsh, Chief Executive Officer, GlyTherix Ltd Don’t miss ProBio and GlyTherix Live Webinar on 6th December Learn More